Capecitabine Market By Indication (Colorectal Cancer, Breast Cancer, Others) , By Drug Type (Branded, Generic) By End User (Hospitals, Homecare, Specialty Clinics, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The global capecitabine market was valued at $0.4 billion in 2023, and is projected to reach $0.7 billion by 2033, growing at a CAGR of 5% from 2024 to 2033.
Capecitabine is an oral chemotherapy medication used in the treatment of various cancers, including breast, colon, and rectal cancers. It belongs to a class of drugs known as antimetabolites, which work by interfering with the growth and spread of cancer cells. Capecitabine is a prodrug, meaning it is converted into its active form, 5-fluorouracil (5-FU), in the body. Once converted, 5-FU inhibits the synthesis of DNA and RNA in cancer cells, leading to their death. Traditional chemotherapy drugs administered intravenously, whereas capecitabine is taken orally, usually in the form of tablets. This offers convenience to patients and allows for outpatient treatment in many cases.
The growth of the capecitabine market is driven by rise in the prevalence of cancer. With the growing number of cancer patients globally, there is surge in demand for the effective treatment option. Moreover, rise in geriatric population has emerged as a significant driver of the capecitabine market. As individuals age, they become more susceptible to developing cancer due to factors such as accumulated genetic mutations, weakened immune systems, and prolonged exposure to carcinogens over their lifetime. This demographic shift toward an aging population has led to a higher prevalence of cancer diagnoses among older adults, creating a greater demand for effective cancer treatments such as capecitabine.
However, adverse effects related to capecitabine, such as anemia, chest discomfort, vomiting, and blood clotting disorders, hamper the growth of the market. On the other hand, product innovation, launches, and diversification present lucrative opportunities for the market players. For instance, in December 2022, Shilpa Medicare Ltd. announced the launch of the Capecitabine 1000 MG dispersible tablet with novel technology of faster dispersion within 90 seconds. The product is supported by required scientific proof and comparative bioequivalence studies and is approved by Central Drugs Standard Control Organisation (CDSCO) —the National Regulatory Authority (NRA) of India, responsible for ensuring the safety, efficacy, and quality of medical products in the country. The product is used for treatment of colorectal and metastatic breast cancer.
Segmentation Overview
The global capecitabine market is segmented into indication, drug type, end user, and region. By indication, the market is divided into colorectal cancer, breast cancer, and others. Depending on drug type, it is categorized into branded and generic. According to end user, the market is classified into hospitals, homecare, specialty centers, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By indication, the breast cancer segment was the largest shareholder in the market in 2023.
Depending on drug type, the branded segment held the highest market share in 2023.
According to end user, the hospitals segment accounted for the maximum share of the market in 2023.
Region wise, North America dominated the capecitabine market in 2023.
Competitive Scenario
The major players operating in the capecitabine market include F. Hoffmann-La Roche Ltd., Mylan N.V, Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Novartis AG, Bayer AG, Eli Lilly and Company, and Merck & Co., Inc. Other players in the market include GlaxoSmithKline Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Lupin, and Alkem Labs Ltd. These players have adopted several strategies, including product diversification & innovation, mergers & acquisitions, and collaborations to maintain their foothold in the market.
Key Market Segments
By Indication
Colorectal Cancer
Breast Cancer
Others
By Drug Type
Branded
Generic
By End User
Hospitals
Homecare
Specialty Clinics
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Pfizer Inc.
Dr. Reddy’s Laboratories Ltd.
Novartis AG
Bayer AG
Eli Lilly and Company.
Merck & Co., Inc.
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- CHAPTER 4: CAPECITABINE MARKET, BY INDICATION
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Indication
- 4.2. Colorectal Cancer
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Breast Cancer
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Others
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- CHAPTER 5: CAPECITABINE MARKET, BY DRUG TYPE
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Drug Type
- 5.2. Branded
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Generic
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- CHAPTER 6: CAPECITABINE MARKET, BY END USER
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By End User
- 6.2. Hospitals
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Homecare
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Specialty Clinics
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- 6.5. Others
- 6.5.1. Key Market Trends, Growth Factors and Opportunities
- 6.5.2. Market Size and Forecast, By Region
- 6.5.3. Market Share Analysis, By Country
- CHAPTER 7: CAPECITABINE MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Indication
- 7.2.3. Market Size and Forecast, By Drug Type
- 7.2.4. Market Size and Forecast, By End User
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Capecitabine Market
- 7.2.6.1. Market Size and Forecast, By Indication
- 7.2.6.2. Market Size and Forecast, By Drug Type
- 7.2.6.3. Market Size and Forecast, By End User
- 7.2.7. Canada Capecitabine Market
- 7.2.7.1. Market Size and Forecast, By Indication
- 7.2.7.2. Market Size and Forecast, By Drug Type
- 7.2.7.3. Market Size and Forecast, By End User
- 7.2.8. Mexico Capecitabine Market
- 7.2.8.1. Market Size and Forecast, By Indication
- 7.2.8.2. Market Size and Forecast, By Drug Type
- 7.2.8.3. Market Size and Forecast, By End User
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Indication
- 7.3.3. Market Size and Forecast, By Drug Type
- 7.3.4. Market Size and Forecast, By End User
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Capecitabine Market
- 7.3.6.1. Market Size and Forecast, By Indication
- 7.3.6.2. Market Size and Forecast, By Drug Type
- 7.3.6.3. Market Size and Forecast, By End User
- 7.3.7. France Capecitabine Market
- 7.3.7.1. Market Size and Forecast, By Indication
- 7.3.7.2. Market Size and Forecast, By Drug Type
- 7.3.7.3. Market Size and Forecast, By End User
- 7.3.8. UK Capecitabine Market
- 7.3.8.1. Market Size and Forecast, By Indication
- 7.3.8.2. Market Size and Forecast, By Drug Type
- 7.3.8.3. Market Size and Forecast, By End User
- 7.3.9. Italy Capecitabine Market
- 7.3.9.1. Market Size and Forecast, By Indication
- 7.3.9.2. Market Size and Forecast, By Drug Type
- 7.3.9.3. Market Size and Forecast, By End User
- 7.3.10. Spain Capecitabine Market
- 7.3.10.1. Market Size and Forecast, By Indication
- 7.3.10.2. Market Size and Forecast, By Drug Type
- 7.3.10.3. Market Size and Forecast, By End User
- 7.3.11. Rest Of Europe Capecitabine Market
- 7.3.11.1. Market Size and Forecast, By Indication
- 7.3.11.2. Market Size and Forecast, By Drug Type
- 7.3.11.3. Market Size and Forecast, By End User
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Indication
- 7.4.3. Market Size and Forecast, By Drug Type
- 7.4.4. Market Size and Forecast, By End User
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Capecitabine Market
- 7.4.6.1. Market Size and Forecast, By Indication
- 7.4.6.2. Market Size and Forecast, By Drug Type
- 7.4.6.3. Market Size and Forecast, By End User
- 7.4.7. China Capecitabine Market
- 7.4.7.1. Market Size and Forecast, By Indication
- 7.4.7.2. Market Size and Forecast, By Drug Type
- 7.4.7.3. Market Size and Forecast, By End User
- 7.4.8. Australia Capecitabine Market
- 7.4.8.1. Market Size and Forecast, By Indication
- 7.4.8.2. Market Size and Forecast, By Drug Type
- 7.4.8.3. Market Size and Forecast, By End User
- 7.4.9. India Capecitabine Market
- 7.4.9.1. Market Size and Forecast, By Indication
- 7.4.9.2. Market Size and Forecast, By Drug Type
- 7.4.9.3. Market Size and Forecast, By End User
- 7.4.10. South Korea Capecitabine Market
- 7.4.10.1. Market Size and Forecast, By Indication
- 7.4.10.2. Market Size and Forecast, By Drug Type
- 7.4.10.3. Market Size and Forecast, By End User
- 7.4.11. Rest of Asia-Pacific Capecitabine Market
- 7.4.11.1. Market Size and Forecast, By Indication
- 7.4.11.2. Market Size and Forecast, By Drug Type
- 7.4.11.3. Market Size and Forecast, By End User
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Indication
- 7.5.3. Market Size and Forecast, By Drug Type
- 7.5.4. Market Size and Forecast, By End User
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Capecitabine Market
- 7.5.6.1. Market Size and Forecast, By Indication
- 7.5.6.2. Market Size and Forecast, By Drug Type
- 7.5.6.3. Market Size and Forecast, By End User
- 7.5.7. Saudi Arabia Capecitabine Market
- 7.5.7.1. Market Size and Forecast, By Indication
- 7.5.7.2. Market Size and Forecast, By Drug Type
- 7.5.7.3. Market Size and Forecast, By End User
- 7.5.8. South Africa Capecitabine Market
- 7.5.8.1. Market Size and Forecast, By Indication
- 7.5.8.2. Market Size and Forecast, By Drug Type
- 7.5.8.3. Market Size and Forecast, By End User
- 7.5.9. Rest of LAMEA Capecitabine Market
- 7.5.9.1. Market Size and Forecast, By Indication
- 7.5.9.2. Market Size and Forecast, By Drug Type
- 7.5.9.3. Market Size and Forecast, By End User
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. F. Hoffmann-La Roche Ltd.
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Mylan N.V.
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Teva Pharmaceutical Industries Ltd.
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. Sanofi
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. Pfizer Inc.
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Dr. Reddy’s Laboratories Ltd.
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. Novartis AG
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Bayer AG
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. Eli Lilly And Company.
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Merck And Co., Inc.
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
- TABLE 1. GLOBAL CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 2. CAPECITABINE MARKET FOR COLORECTAL CANCER, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 3. CAPECITABINE MARKET FOR BREAST CANCER, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 4. CAPECITABINE MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 5. GLOBAL CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 6. CAPECITABINE MARKET FOR BRANDED, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 7. CAPECITABINE MARKET FOR GENERIC, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 8. GLOBAL CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 9. CAPECITABINE MARKET FOR HOSPITALS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 10. CAPECITABINE MARKET FOR HOMECARE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 11. CAPECITABINE MARKET FOR SPECIALTY CLINICS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 12. CAPECITABINE MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 13. CAPECITABINE MARKET, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 14. NORTH AMERICA CAPECITABINE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 15. NORTH AMERICA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 16. NORTH AMERICA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 17. NORTH AMERICA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 18. U.S. CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 19. U.S. CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 20. U.S. CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 21. CANADA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 22. CANADA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 23. CANADA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 24. MEXICO CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 25. MEXICO CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 26. MEXICO CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 27. EUROPE CAPECITABINE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 28. EUROPE CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 29. EUROPE CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 30. EUROPE CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 31. GERMANY CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 32. GERMANY CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 33. GERMANY CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 34. FRANCE CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 35. FRANCE CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 36. FRANCE CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 37. UK CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 38. UK CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 39. UK CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 40. ITALY CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 41. ITALY CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 42. ITALY CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 43. SPAIN CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 44. SPAIN CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 45. SPAIN CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 46. REST OF EUROPE CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 47. REST OF EUROPE CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 48. REST OF EUROPE CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 49. ASIA-PACIFIC CAPECITABINE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 50. ASIA-PACIFIC CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 51. ASIA-PACIFIC CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 52. ASIA-PACIFIC CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 53. JAPAN CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 54. JAPAN CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 55. JAPAN CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 56. CHINA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 57. CHINA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 58. CHINA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 59. AUSTRALIA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 60. AUSTRALIA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 61. AUSTRALIA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 62. INDIA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 63. INDIA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 64. INDIA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 65. SOUTH KOREA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 66. SOUTH KOREA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 67. SOUTH KOREA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 68. REST OF ASIA-PACIFIC CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 69. REST OF ASIA-PACIFIC CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 70. REST OF ASIA-PACIFIC CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 71. LAMEA CAPECITABINE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 72. LAMEA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 73. LAMEA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 74. LAMEA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 75. BRAZIL CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 76. BRAZIL CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 77. BRAZIL CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 78. SAUDI ARABIA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 79. SAUDI ARABIA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 80. SAUDI ARABIA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 81. SOUTH AFRICA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 82. SOUTH AFRICA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 83. SOUTH AFRICA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 84. REST OF LAMEA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 85. REST OF LAMEA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
- TABLE 86. REST OF LAMEA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 87. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
- TABLE 88. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
- TABLE 89. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
- TABLE 90. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
- TABLE 91. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 92. MYLAN N.V.: KEY EXECUTIVES
- TABLE 93. MYLAN N.V.: COMPANY SNAPSHOT
- TABLE 94. MYLAN N.V.: OPERATING SEGMENTS
- TABLE 95. MYLAN N.V.: PRODUCT PORTFOLIO
- TABLE 96. MYLAN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 97. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 98. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
- TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 101. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 102. SANOFI: KEY EXECUTIVES
- TABLE 103. SANOFI: COMPANY SNAPSHOT
- TABLE 104. SANOFI: OPERATING SEGMENTS
- TABLE 105. SANOFI: PRODUCT PORTFOLIO
- TABLE 106. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 107. PFIZER INC.: KEY EXECUTIVES
- TABLE 108. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 109. PFIZER INC.: OPERATING SEGMENTS
- TABLE 110. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 111. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 112. DR. REDDY’S LABORATORIES LTD.: KEY EXECUTIVES
- TABLE 113. DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
- TABLE 114. DR. REDDY’S LABORATORIES LTD.: OPERATING SEGMENTS
- TABLE 115. DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
- TABLE 116. DR. REDDY’S LABORATORIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 117. NOVARTIS AG: KEY EXECUTIVES
- TABLE 118. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 119. NOVARTIS AG: OPERATING SEGMENTS
- TABLE 120. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 121. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 122. BAYER AG: KEY EXECUTIVES
- TABLE 123. BAYER AG: COMPANY SNAPSHOT
- TABLE 124. BAYER AG: OPERATING SEGMENTS
- TABLE 125. BAYER AG: PRODUCT PORTFOLIO
- TABLE 126. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 127. ELI LILLY AND COMPANY.: KEY EXECUTIVES
- TABLE 128. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
- TABLE 129. ELI LILLY AND COMPANY.: OPERATING SEGMENTS
- TABLE 130. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
- TABLE 131. ELI LILLY AND COMPANY.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 132. MERCK AND CO., INC.: KEY EXECUTIVES
- TABLE 133. MERCK AND CO., INC.: COMPANY SNAPSHOT
- TABLE 134. MERCK AND CO., INC.: OPERATING SEGMENTS
- TABLE 135. MERCK AND CO., INC.: PRODUCT PORTFOLIO
- TABLE 136. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- FIGURE 1. GLOBAL CAPECITABINE MARKET, 2024 - 2033
- FIGURE 2. SEGMENTATION OF CAPECITABINE MARKET, 2024 - 2033
- FIGURE 3. TOP INVESTMENT POCKET IN CAPECITABINE MARKET
- FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 7. LOW THREAT OF SUBSTITUTION
- FIGURE 8. HIGH COMPETITIVE RIVALRY
- FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCAPECITABINE MARKET
- FIGURE 10. GLOBAL CAPECITABINE MARKET SEGMENTATION, BY INDICATION
- FIGURE 11. CAPECITABINE MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 12. CAPECITABINE MARKET FOR BREAST CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 13. CAPECITABINE MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 14. GLOBAL CAPECITABINE MARKET SEGMENTATION, BY DRUG TYPE
- FIGURE 15. CAPECITABINE MARKET FOR BRANDED, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 16. CAPECITABINE MARKET FOR GENERIC, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 17. GLOBAL CAPECITABINE MARKET SEGMENTATION, BY END USER
- FIGURE 18. CAPECITABINE MARKET FOR HOSPITALS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 19. CAPECITABINE MARKET FOR HOMECARE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 20. CAPECITABINE MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 21. CAPECITABINE MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 26. COMPETITIVE DASHBOARD
- FIGURE 27. COMPETITIVE HEATMAP: CAPECITABINE MARKET
- FIGURE 28. TOP PLAYER POSITIONING, 2023
- FIGURE 29. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 30. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 31. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 32. MYLAN N.V.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 33. MYLAN N.V.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 34. MYLAN N.V.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 35. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 36. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 37. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 38. SANOFI: NET SALES, 2021-2023 ($BILLION)
- FIGURE 39. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 40. SANOFI: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 41. PFIZER INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 42. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 43. PFIZER INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 44. DR. REDDY’S LABORATORIES LTD.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 45. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 46. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 47. NOVARTIS AG: NET SALES, 2021-2023 ($BILLION)
- FIGURE 48. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 49. NOVARTIS AG: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 50. BAYER AG: NET SALES, 2021-2023 ($BILLION)
- FIGURE 51. BAYER AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 52. BAYER AG: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 53. ELI LILLY AND COMPANY.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 54. ELI LILLY AND COMPANY.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 55. ELI LILLY AND COMPANY.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 56. MERCK AND CO., INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 57. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 58. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2023 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook